Chemicals and pharmaceuticals · ENTO

First Wave BioPharma, Inc.

12 filings mentioning 10 of the compliance and risk topics we track. Every row links to the filing on EDGAR.

12filings we hold
10topics disclosed
Chemicals and pharmaceuticalsindustry
FLbased in

Across 12 filings we hold, First Wave BioPharma, Inc. has written down 10 of the topics we track. That places it 203 of 737 companies we hold in chemicals and pharmaceuticals, by how much we have collected.

ENTO Chemicals and pharmaceuticals

What this obligates

Every instrument in our corpus that governs something First Wave BioPharma, Inc. has written into a filing. Not what they said. What applies once they have said it.

NIST Cybersecurity Framework 2.078
ISO/IEC 42001:202361
ISO 27001:202242
NIST AI Risk Management Framework (AI RMF 1.0)41
ISO 37001:201639
ISO 22301:201938
ASD Strategies to Mitigate Cyber Security Incidents29
ISO 3700126
GDPR26
ISO/IEC 27701:201921

10 frameworks, 401 controls between them, deduplicated across topics.

What it discloses

Tracked topics appearing in this company's filings, most frequent first.

Internal Control21
Business Continuity9
Artificial Intelligence4
Third Party Risk Management4
Material Weakness2
Restatement2
Ransomware2
Consent Order1
Enforcement Action1
Data Breach1

Bars are scaled against this company's most frequent topic, not against the market. The table below has the exact counts.

TopicFilingsMost recent
Internal Control212026-07-06
Business Continuity92022-11-14
Artificial Intelligence42026-04-13
Third Party Risk Management42026-05-01
Material Weakness22024-03-14
Restatement22025-03-07
Ransomware22026-05-01
Consent Order12019-07-22
Enforcement Action12023-10-10
Data Breach12026-04-13

When it filed

Filings we hold, by year. Hover a bar for the count.

19
20
21
22
23
24
25
26

Recent filings

FiledFormItem
2026-07-068-KEntry into a material agreement, Item 3.02, Financial statements and exhibitsfiling
2026-05-148-KEntry into a material agreement, Item 3.02, Financial statements and exhibitsfiling
2026-05-0110-Kfiling
2026-04-138-K/AFinancial statements and exhibitsfiling
2025-10-228-KEntry into a material agreement, Item 2.03, Financial statements and exhibitsfiling
2025-10-068-KEntry into a material agreement, Completion of an acquisition, Item 3.02filing
2025-04-0910-K/Afiling
2025-04-0110-Kfiling
2025-03-078-KEntry into a material agreement, Delisting or listing rule failure, Director or officer departurefiling
2024-05-088-K/AFinancial statements and exhibitsfiling
2024-03-2910-Kfiling
2024-03-148-KEntry into a material agreement, Completion of an acquisition, Item 2.03filing

Others in chemicals and pharmaceuticals

The companies we hold most on in the same industry. Each opens side by side with this one.

CompanyFilings
OPKOPKO HEALTH, INC.12compare →
FGENFIBROGEN INC12compare →
PTNPALATIN TECHNOLOGIES INC12compare →
OTLCOncotelic Therapeutics, Inc.12compare →
NKTRNEKTAR THERAPEUTICS12compare →
APALEXION PHARMACEUTICALS, INC.12compare →
New here? Signals tracks the compliance and risk language public companies put into their SEC filings, and cross-references it against 723 frameworks and 20,473 controls. See what moved today or check how much of a framework you already cover.

What this page is

Every row comes from SEC full-text search over this company's filings, matched against the compliance and risk phrases we track. It is a record of what the company itself wrote down in documents it is legally accountable for. It is not an assessment of the company, a rating, or a claim about how well it manages anything.

A phrase appearing in a filing frequently means the risk section mentions it, not that an event occurred. Where an item number indicates an actual event, the Item column says so.

All of chemicals and pharmaceuticals · All companies · Today's edition